Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About Cytochroma

Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD. The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stages of development.In January 2013, Cytochroma was acquired by OPKO Health. The valuation of Cytochroma was undisclosed. Other terms of the deal were not released.

Headquarters Location

100 Allstate Parkway Suite 600

Markham, Ontario, L3R 6H3,



Missing: Cytochroma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cytochroma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cytochroma Patents

Cytochroma has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Reducing agents, Metal halides, Monoclinic minerals, Lanthanides, Lanthanide minerals


Application Date


Grant Date



Related Topics

Reducing agents, Metal halides, Monoclinic minerals, Lanthanides, Lanthanide minerals



Latest Cytochroma News

Angel Academe invests in Cytochroma

Jan 5, 2022

Angel Academe has announced that their latest investment is in Cytochroma, a life sciences company which provides ethnically diverse as well as sustainable and accurate alternatives to animal testing in drug discovery and development. Read the full story here. The post Angel Academe invests in Cytochroma appeared first on UK Business Angels Association.

Cytochroma Frequently Asked Questions (FAQ)

  • When was Cytochroma founded?

    Cytochroma was founded in 1996.

  • Where is Cytochroma's headquarters?

    Cytochroma's headquarters is located at 100 Allstate Parkway, Markham.

  • What is Cytochroma's latest funding round?

    Cytochroma's latest funding round is Acquired.

  • How much did Cytochroma raise?

    Cytochroma raised a total of $24.4M.

  • Who are the investors of Cytochroma?

    Investors of Cytochroma include OPKO Health, VenGrowth Capital Partners, CDP Capital, T2C2 Capital, Novo Holdings and 8 more.

  • Who are Cytochroma's competitors?

    Competitors of Cytochroma include Humanetics, Neurelis, Annovis Bio, Clovis Oncology, Intarcia Therapeutics, Akebia Therapeutics, Meritage Pharma, Auxilium Pharmaceuticals, Auris Medical, Revance Therapeutics and 23 more.

Compare Cytochroma to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.

Aestus Therapeutics Logo
Aestus Therapeutics

Aestus Therapeutics, Inc. is a translational medicine company focused on the treatment of disorders of the nervous system. Aestus's core technology aims to utilize a process for mining both public gene expressions and pharmaceutical data (the Aestus engine).

Slate Pharmaceuticals

Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.


Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.